Fallopian Tube
| Treatment Stage | Protocol Title | ClinicalTrials.Gov Link | Penn Research Coordinator | Am I Eligible? |
|---|---|---|---|---|
| Front Line Maintenance | GOG 3102: A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy | NCT07318558 | Joanna Lin | Eligibility |
| Recurrent | GOG 3096: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
NCT06161025 | Kristina Powell | Eligibility Criteria |
| Recurrent | GOG 3066: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04814108 | Kristina Powell | |
| Recurrent | STAR-101: A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma | NCT05568680 | Andrea Standish, RN |
ON HOLD |
| Recurrent | NRG-GY031: A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer | NCT05950464 | Andrea Standish, RN |
ON HOLD |
| Recurrent | Phase 1/2 Study of REGN5668 (MUC16 X CD28, A Costimulatory Bispecific) Administered in Combination with Cemiplimab or REGN4018 (MUC16 X CD3) | NCT04590326 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | GOG 3115: A Single Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with Folate Receptor Alpha Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT04606914 | Joanna Lin | Eligibility Criteria |
| Recurrent | GOG 3126: A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations with Mirvetuximab Soravtansine in Subjects with Ovarian Cancer (FLORENZA) | NCT07059845 | Kristina Powell | Eligibility Criteria |
| Recurrent | GOG 3133: FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer | NCT07213804 | Anna Duffy | Eligibility Criteria |
| Recurrent (Clear Cell) | Phase 2 Study of Senaparib in Combination with Temozolomide in ARID1A mutation associated Ovarian Cancer | NCT06617923 | Joanna Lin | Eligibility Criteria |
| Maintenance | UPROAR: A phase II evaluation of maintenance therapy combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer | NCT05887609 | Kristina Powell | Eligibility Criteria |
| Maintenance | NRG-GY036: A Phase III Trial of One Vs Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy | NCT06580314 | Joanna Lin | Eligibility Criteria |